Chelsea Therapeutics International Ltd
Chelsea Therapeutics International — Investor Presentation (July 2013)
27 slides from Chelsea Therapeutics International's investor presentation, Jul 9, 2013
Slide 1: Chelsea Therapeutics Corporate Overview July 2013
Chelsea Therapeutics Corporate Overview July 2013 © 2004 - 2013 Chelsea Therapeutics, Inc.
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation is being provided for informational and discussion purposes . This presentation is not intended to provide and should not be relied upon as investment advice or an opinion regarding the appropriateness or suitability of any investment . Nothing herein s
Slide 3: Lead Drug Candidate is Northera (droxidopa)
Lead Drug C andidate is Northera (droxidopa) Oral “pro - drug ” of norepinephrine; directly metabolized to form norepinephrine • Replenishes diminished level of natural neurotransmitter, norepinephrine, within the autonomic nervous system • Unique mechanism of action limits side effects seen with ot
Slide 4: Neurogenic Orthostatic Hypotension
Neurogenic Orthostatic Hypotension Neurogenic Orthostatic Hypotension (Neurogenic OH or NOH): Sudden, potentially dangerous, fall in blood pressure when standing from a sitting or lying position • Caused by diminished synthesis and/or release of the norepinephrine used by autonomic nerves to regulat
Slide 5: The Neurogenic OH Patient
The Neurogenic OH Patient Parkinson’s Disease • Prevalence of disease: 120 cases per 100,000 population • Prevalence of symptomatic Neurogenic OH: approx. 18% Multiple System Atrophy • Prevalence of disease: 1 - 9 cases per 100,000 population • Prevalence of symptomatic Neurogenic OH: approx. 81% Pu
Slide 6: NOH: Current Therapeutic Landscape
NOH: Current Therapeutic Landscape NASDAQ: CHTP 6 Midodrine (ProAmatine ®) … available in generic form • Alpha agonist - undifferentiated pressor effect with troublesome side effects • Black box warning for supine hypertension…22% at 10 mg dose • Paresthesia (tingling, pricking or numbness of skin (
Slide 7: Existing Symptomatic NOH Market
Existing Symptomatic NOH Market Market size: • Approximately 145K patients taking midodrine and/or fludrocortisone for NOH (2010 data) • Growing market with aging US population NO existing promotion or Pharma sponsored awareness programs Concentrated prescriber base: • Small identified group of Neur
Slide 8: Northera: US Commercial Opportunity in NOH
Northera: US Commercial Opportunity in NOH Projected US sales potential of $300 - $375 million within 3 - 5 years of launch Assumptions: • Differentiated product label would allow for an attractive US Pricing Model • Majority of payers will cover but with high co - pays and/or as second line to gene
Slide 9: Regulatory Landscape
Regulatory Landscape Complete Response Letter (CRL) • Requirement for an additional clinical study showing efficacy to support Study 301 • Inconsistencies in the overall findings (failure of Study 302, 303) • Disproportionate contribution of specific clinical sites to the overall results of Study 30
Slide 10: NDA Resubmission: Basis for Approval
NDA Resubmission: Basis for Approval Accelerated Approval; allows durability to be proven post - approval • Proposed two complementary post - market trials • Study 1 – Long term (12 week) study, n~450. Planned initiation in Q4, 2013 • Study 2 – Design to be discussed with FDA during review and initi
Slide 11: Two Independent Studies: Highly Consistent Efficacy
Two Independent Studies: Highly Consistent Efficacy Mean +SEM Improvement OHSA Item #1 from Baseline to Week 1 NASDAQ: CHTP 11
Slide 12: Two Independent Studies: Highly Consistent Efficacy
Two Independent Studies: Highly Consistent Efficacy Proportion of Patients with ≥50% Improvement in OHSA Item 1 at Week 1 NASDAQ: CHTP 12
Slide 13: Two Independent Studies: Highly Consistent Efficacy
Two Independent Studies: Highly Consistent Efficacy Change in Standing SBP at Week 1 NASDAQ: CHTP 13
Slide 14: Study 306B: Striking Reduction in Falls
Study 306B: Striking Reduction in Falls Droxidopa also associated with a reduction in fall related injuries • 25.6% of placebo patients injured • 16.9% of droxidopa patients injured Includes debilitating injuries in Placebo patients • Traumatic Brain Injury • Fibula Fracture • Facial Bones Fracture
Slide 15: Potential Review or Advisory Committee Issues
Potential Review or Advisory Committee Issues Potential Issue Chelsea Strategy Disproportionate contribution of two Ukrainian clinical sites to Study 301 results • Audits at sites have identified no major issues with study conduct or good clinical practices • Sensitivity analyses excluding these sit
Slide 16: Potential Review or Advisory Committee Issues
Potential Review or Advisory Committee Issues Potential Issue Chelsea Strategy Use of a modified Intent To Treat analysis in Study 306B; More dropouts in droxidopa group during titration • The mITT analysis is an appropriate population, similar to real world use • Multiple sensitivity analyses on dr
Slide 17: Durability: Suggestion of Durable Clinical Benefit
Durability: Suggestion of Durable Clinical Benefit • Study 306 was designed to capture durable (8 week) clinical benefit • Meta - analyses of Study 306 (A+B) show suggestion of durable benefit • Trends favoring droxidopa on most endpoints • Statistical significance in certain analyses • Appears 306A
Slide 18: Durability: OHSA Item (Dizziness) Mean Changes
Durability: OHSA Item 1 (Dizziness) Mean Changes (Study 306AB) -3 -2.5 -2 -1.5 -1 -0.5 0 BL 1 2 3 4 5 6 7 8 Weeks of Stable Dose 5.1 3.4 3.6 3.1 3.6 p =0.077 Placebo Droxidopa Mean Change in OHSA Item 1 Baseline to Week 8 ** *p<0.05 **p<0.01 NASDAQ: CHTP 18
Slide 19: Durability: OHSA Item (Dizziness) Responders
Durability: OHSA Item 1 (Dizziness) Responders , Week 8 (Study 306AB) 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 ≥ 1 Unit ≥ 2 Unit ≥ 3 Unit ≥ 4 Unit ≥ 25% ≥ 50% Placebo (N=92) Droxidopa (N=84) Percentage of Patients Improvement From Baseline * * *p<0.05 NASDAQ: CHTP 19
Slide 20: Durability: Standing Systolic BP Mean Changes
Durability: Standing Systolic BP Mean Changes (Study 306AB) -4 -2 0 2 4 6 8 10 12 BL 1 2 3 4 5 6 7 8 Weeks of Stable Dose 5.1 3.4 3.6 3.1 3.6 Placebo Droxidopa Mean Change in Lowest Standing SBP Baseline to Week 8 ** *p<0.05 **p<0.01 NASDAQ: CHTP 20
Slide 21: Consistent Results Across Studies
Consistent Results Across Studies -4 -3 -2 -1 0 1 2 3 4 Change in Dizziness/Lightheadedness Study 301 Study 306 Study 360A Study 302 Study 302 Study 360B Induction Designs Withdrawal Designs Favors Placebo Favors Droxidopa p<0.001 n=162 p=0.008 n=197 p=ns n=50 p<0.018 n=147 p=ns n=101 p=ns n=75 NASD
Slide 22: Strong Safety Profile Across Multiple Studies
Strong Safety Profile Across Multiple Studies Study 301/302 1 - 2 wk double - blind Study 306AB 8 - 10 wk double - blind Study 303/304 ~1 year open label NORTHERA (N=131) PLACEBO (N=132) NORTHERA (N=114) PLACEBO (N=108) NORTHERA (N=422) % % % % % Patients with AEs 22.9 23.5 79.8 80.6 76.1 Patients w
Slide 23: Strong Safety Profile Across Multiple Studies
Strong Safety Profile Across Multiple Studies AEs ≥5% in either group of Study 301/302 or 306 Study 301/302 1 - 2 wk double - blind Study 306AB 8 - 10 wk double - blind Study 303/304 ~1 year open label NORTHERA (N=131) PLACEBO (N=132) NORTHERA (N=114) PLACEBO (N=108) NORTHERA (N=422) % % % % % Heada
Slide 24: Study 306AB: Incidence of Supine Hypertension
Study 306AB: Incidence of Supine Hypertension NORTHERA (N=114) PLACEBO (N=108) N (%) N (%) SBP > 200 mmHg 4 (3.5%) 1 (0.9%) SBP > 180 mmHg 9 (7.9%) 5 (4.6%) SBP > 160 mmHg 33 (28.9%) 26 (24.1%) Note: Incidence of supine hypertension defined by 3 consecutive blood pressure measurements during Orthost
Slide 25: Clinical & Regulatory Milestones
Clinical & Regulatory Milestones • July 3, 2013: Resubmitted Northera NDA: • Data from new supportive Phase III studies (306A/B ) • Final open - label safety extension study data (304) • Expanded 650 patient safety database • New bioequivalence study to support the 300 mg dose • 4Q2013: Begin New Cl
Slide 26: Key Financial Information
Key Financial Information Cash and Cash Equivalents at 3/31/13 $25.1 million • We anticipate this will cover our operating expenses into Q3 - 2014 • Cash usage includes costs for NDA filing and starting a new study in Q4 - 2013 • Costs related to NDA approval and commercialization are not included C
Slide 27: Chelsea Therapeutics Corporate Overview July 2013
Chelsea Therapeutics Corporate Overview July 2013 © 2004 - 2013 Chelsea Therapeutics, Inc.
Chelsea Therapeutics International — Investor Presentation (July 2013) on 6ix